Acceleron Pharma gets grant for treatment of spinal muscular atrophy using ALK4:ACTIRiib antagonists

Discover how Acceleron Pharma's patent for treating spinal muscular atrophy with ALK4:ActRIIB antagonists aims to increase muscle mass, strength, and bone density in patients.

Apr 11, 2024 - 00:00

Discover how Acceleron Pharma's patent for treating spinal muscular atrophy with ALK4:ActRIIB antagonists aims to increase muscle mass, strength, and bone density in patients.

Read the original article

Tags:

Previous Article

TORL scores $158m in Series B2 to advance ADC cancer therapies

MorphoSys gets grant for novel compounds for treating diseases associated with m...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

AIFA’s horizon scanning 2024 predictions suggest an influx of ATMPs

AIFA’s horizon scanning 2024 predictions suggest an inf...

May 31, 2024

Opinion: Do chatbots have more time to be empathetic than physicians?

Opinion: Do chatbots have more time to be empathetic th...

May 17, 2023

MSD secures full approval for Keytruda’s use in MSI-high solid tumours

MSD secures full approval for Keytruda’s use in MSI-hig...

Mar 31, 2023